製品番号: HY-N4246

Bacopaside I

(別名: バコパシドI)

カスタマーレビュー

Based on 1 Customer Validation

Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.20%
CAS 番号: 382148-47-2
分子式: C₄₆H₇₄O₂₀S
分子量:979.13

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Bacopaside I 構造式

CAS 番号: 382148-47-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

MAO-A

PKC アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

PI3K アイソフォーム固有の製品をすべて表示 :

Monoamine Oxidase アイソフォーム固有の製品をすべて表示 :

MAO-A
MAO-B

体外実験

Bacopaside I (117-178 μM; 50 mins-2 h) potently and selectively inhibits AQP1-mediated osmotic water permeability in Xenopus laevis oocytes with an IC₅₀ of 117 μM; Bacopaside I shows no activity against AQP4^[1].
Bacopaside I (50-100 μM; 2 h) inhibits cGMP-dependent ion conductance of AQP1 in Xenopus laevis oocytes, and the blocking effect at 100 μM is stronger than that at 50 μM after 2 h of incubation^[1].
Bacopaside I (48-50 μM; 24 h) inhibits the migration of HT29 colon cancer cells with high AQP1 expression, with an IC₅₀ of 48 μM, and impairs the directional motility of the cells^[1].
Bacopaside I (50-75 μM; 24 h) shows no cytotoxicity against HT29 colon cancer cells at concentrations up to 75 μM after 24 h of incubation^[1].
Treatment with Bacopaside I (5-10 μM; 3-4 d) for 3 days reduces the proliferative activity of MDA-MB-231, T47D, MCF7 and BT-474 breast cancer cell lines; treatment for 4 days decreases the migratory capacity of breast cancer cell lines^[2].
Combination treatment with Bacopaside I (5-10 μM; 24 h) and Bacopaside II reduces the transcript expression of AQP1 in MDA-MB-231 breast cancer cells, with an IC₅₀ of 13 μM for inhibiting its activity^[2].
Bacopaside I (administered at 5-25 μM for a total of 60 min, with treatment initiated before and maintained during 45 min of OGD) potently protects organotypic hippocampal slice cultures against OGD-induced neuronal injury by inhibiting apoptosis and necrosis, and the protective activity at 25 μM is superior to that at 5 μM^[3].
Bacopaside I (administered at 25 μM before and during 45 minutes of OGD treatment, with a total intervention duration of 60 min) exerts neuroprotective effects against OGD-induced injury in organotypic hippocampal slice cultures. This effect depends on the PKC and PI3K/Akt signaling pathways, but is independent of the ERK signaling pathway or cholinergic receptor activation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay^[1]

Cell Line:

AQP1-high-expressing human HT29 colon cancer cells
Concentration:

48 μM (IC₅₀ for migration inhibition); 50 μM
Incubation Time:

24 h
Result:

Dose-dependently inhibited HT29 cell migration measured by wound closure, with an IC₅₀ of 48 μM.
Significantly reduced HT29 cell migration into the wound area after 24 h incubation.
Induced compressed, non-directional movement trajectories and shorter mean total distance traveled by cells over 24 h compared to vehicle-treated cells.

Cell Viability Assay^[2]

Cell Line:

MDA-MB-231, T47D, MCF7, BT-474 breast cancer cell lines
Concentration:

IC₅₀ values
Incubation Time:

24 h
Result:

Potently reduced cell viability with half maximal inhibitory concentrations (IC₅₀) of 99 μM (95% CI 91-109) for MDA-MB-231, 89 μM (95% CI 73-109) for T47D, 83 μM (95% CI 79-87) for MCF7, and 59 μM (95% CI 56-63) for BT-474.

Real Time qPCR^[2]

Cell Line:

MDA-MB-231, T47D, BT-474 breast cancer cell lines
Concentration:

5 μM (in combination with 2.5 μM or 5 μM Bacopaside II); 10 μM (in combination with 2.5 μM Bacopaside II)
Incubation Time:

24 h
Result:

Reduced AQP1 transcript expression by 1.8-fold relative to vehicle (p = 0.004) in MDA-MB-231 cells treated with 5 μM Bacopaside I + 2.5 μM Bacopaside II.
Reduced AQP1 transcript expression by 2.5-fold relative to vehicle (p < 0.0001) in MDA-MB-231 cells treated with 5 μM Bacopaside I + 5 μM Bacopaside II.
Showed no significant effect on AQP1 transcript expression in T47D or BT-474 cells.

Cell Viability Assay^[2]

Cell Line:

MDA-MB-231 breast cancer cell line
Concentration:

13 μM (in combination with 2.5 μM Bacopaside II)
Incubation Time:

24 h
Result:

Exhibited an IC₅₀ of 13 μM (95% CI 10-16 μM) in combination with 2.5 μM Bacopaside II, representing a synergistic interaction with a combination index (CIx) of 0.270 (95% CI 0.240-0.301).

体内実験

Bacopaside I (50 mg/kg; oral; daily; 7 days) causes no adverse effects in Swiss-albino mice^[2].
Bacopaside I (oral route) exerts neuroprotective effects in rats with cerebral ischemia-induced injury by reducing neurological deficits, infarct volume, and edema, and by normalizing brain ATP, antioxidant enzyme, ATPase, and MDA levels^[4].
Bacopaside I exhibits antidepressant-like activity in CUMS-exposed mice by reversing hypothalamic-pituitary-adrenal (HPA) axis hyperactivity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss-albino mice^[2]
Dosage:

50 mg/kg
Administration:

oral; daily; 7 days
Result:

Showed no adverse effects.

化学情報

CAS 番号 382148-47-2
性状 Solid
分子量 979.13
分子式 C₄₆H₇₄O₂₀S
Color Off-white to light yellow
SMILES

C[C@]12[C@@]34[C@@](CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](O)CO6)O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)COS(=O)(O)=O)O[C@]8([H])O[C@@H](CO)[C@H](O)[C@H]8O)CC5)C)([H])CC2)C)([H])[C@]9([H])[C@@](OC4)(OC[C@@H](C=C(C)C)[C@@]9(O)C)C3
別名

バコパシドI
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (102.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0213 mL

5.1066 mL

10.2131 mL

5 mM

0.2043 mL

1.0213 mL

2.0426 mL

10 mM

0.1021 mL

0.5107 mL

1.0213 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (288 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Pei JV, et al. Differential Inhibition of Water and Ion Channel Activities of Mammalian Aquaporin-1 by Two Structurally Related Bacopaside Compounds Derived from the Medicinal Plant Bacopa monnieri. Mol Pharmacol. 2016;90(4):496-507. [Content Brief]

[2]. Palethorpe HM, et al. Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. Molecules. 2019;24(19):3539. Published 2019 Sep 30. [Content Brief]

[3]. Le XT, et al. Protective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanism. J Ethnopharmacol. 2015;164:37-45. [Content Brief]

[4]. Sekhar VC, et al. Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I. Curr Neuropharmacol. 2019;17(5):438-446. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.0213 mL	5.1066 mL	10.2131 mL	25.5329 mL
	5 mM	0.2043 mL	1.0213 mL	2.0426 mL	5.1066 mL
	10 mM	0.1021 mL	0.5107 mL	1.0213 mL	2.5533 mL
	15 mM	0.0681 mL	0.3404 mL	0.6809 mL	1.7022 mL
	20 mM	0.0511 mL	0.2553 mL	0.5107 mL	1.2766 mL
	25 mM	0.0409 mL	0.2043 mL	0.4085 mL	1.0213 mL
	30 mM	0.0340 mL	0.1702 mL	0.3404 mL	0.8511 mL
	40 mM	0.0255 mL	0.1277 mL	0.2553 mL	0.6383 mL
	50 mM	0.0204 mL	0.1021 mL	0.2043 mL	0.5107 mL
	60 mM	0.0170 mL	0.0851 mL	0.1702 mL	0.4255 mL
	80 mM	0.0128 mL	0.0638 mL	0.1277 mL	0.3192 mL
	100 mM	0.0102 mL	0.0511 mL	0.1021 mL	0.2553 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Bacopaside I

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Nuclear Receptor Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

PKC アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

PI3K アイソフォーム固有の製品をすべて表示

Monoamine Oxidase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bacopaside I 関連分類

HY-N4246 関連分類